ClinicalTrials.gg
TerminatedNCT00407797PREPS MEXICOUpdated Jan 25, 2021Results posted

Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial

A Phase 4 interventional study of Pregabalin in Partial Seizures, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 8 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
136
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing pregabalin in Seizures — none open to participants now, none under way, none of them phase 3. Pregabalin · Seizures.

Enrollment
9th of 10
136 · median 276
Started
2007
with 2 others
Phase 4
2 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
9 of 10
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 10 studies testing pregabalin in Seizures, this one is the 9th largest by enrollment, is one of 3 that started in 2007, is one of 2 in phase 4, and was the 5th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

None of the 10 studies testing pregabalin in Seizures is open now. The open studies under Seizures, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing pregabalin in Seizures as a file.
02

Study summary

The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID (75 to 300mg day titration, BID) to existing standard AED (Antiepileptic drugs).

Read the detailed description

This study was terminated on 17 March 2009 due to delayed enrollment. The decision to terminate the trial was not based on any safety concerns, but rather on timelines and the difficulty in enrolling patients in this open label, single group study.

03

Conditions studied

  • Partial Seizures

Keywords

  • Lyrica
  • Epilepsies - Partial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female who are diagnosed of partial seizure (simple partial, complex partial, partial seizure secondarily generalized) as defined in the international league of epilepsy classification of seizure.

Exclusion criteria

Exclusion Criteria:

  • Patients having a treatable cause of seizure, currently receiving vigabatrin, having a progressive neurological or systemic disorder.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Drug: Pregabalin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in 28 Day Partial Seizure Rate During Treatment Observation Phase

    28-day seizure rate (at observation period \[obs\]) = \[(number of seizures obs ) divided by (duration of period based on observed last dosing date and Visit 3 \[Week 9\] date)\] \* 28. Percent change = \[(28-day seizure rate obs minus 28-day seizure rate at baseline \[b\]) divided by 28-day seizure rate b\] \* 100. Negative values indicate a decrease in seizure frequency and positive values reflect an increase in seizure frequency.

    Time frame: Week 9 to Week 21 or End of Treatment (early termination)

Secondary outcomes

  1. Response Ratio (RR)

    Response ratio (RR) = comparison between baseline 28-seizure frequency with the 12 week observation phase. RR = \[(28-day seizure rate in observation period \[obs\] minus 28-day seizure rate at baseline \[b\] ) divided by (28-day seizure rate obs plus 28-day seizure rate b)\] \* 100. Range: -100 to 100; negative values for the RR indicate reductions in seizures.

    Time frame: Week 9 to Week 21 or End of Treatment (early termination)

  2. Percent Change From Baseline in 28-Day Partial Seizure Frequency at Week 21

    Percent change from Baseline = \[(28-day seizure rate at 21 weeks minus 28-day seizure rate at baseline \[b\]) divided by (28-day seizure rate b) \* 100. Negative values indicate a decrease in seizure frequency, positive values reflect an increase in seizure frequency.

    Time frame: Week 21 or End of Treatment (early termination)

  3. Percent Change From Baseline in Seizure Frequency in Participants Who Had <=6 Seizures and >6 Seizures During the Baseline Period

    Negative values indicate a decrease in seizure frequency; positive values reflect an increase in seizure frequency.

    Time frame: Week 9 to Week 21 or End of Treatment (early termination)

  4. Percent of Seizure- Free Participants During the Treatment Observation Period

    Seizure-free = no seizures during observation period (100 percent reduction in seizures from baseline).

    Time frame: Week 9 to Week 21 or Early Termination (end of treatment)

  5. Percent of Seizure Free Participants During the Last 4 Weeks of the Treatment Observation Period

    Seizure-free = no seizures during last 4 weeks of observation period (100 percent reduction in seizures from baseline).

    Time frame: Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)

  6. Percent of Participants With >=50% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period

    Time frame: Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)

  7. Percent of Participants With >=75% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period

    Time frame: Week 17 through Week 21 (or Last 4 Weeks of Treatment after Week 9)

  8. Treatment Satisfaction: Patient General Impression to Change (PGIC)

    Patient General Impression to Change (PGIC): participant rated instrument to measure participant's change in overall status since beginning study medication on a 7-point scale; range: 1 (very much improved) to 7 (very much worse). Not done = participant did not complete the PGIC.

    Time frame: Week 21, LOCF

  9. Change From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS)

    Participant rated questionnaire to assess sleep quality and quantity; 9-item overall sleep problems index and 7 subscales. Sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy subscale scores (s) rated 1 (all the time) to 6 (none of the time); transformed s; total range (r): 0 to 100; higher s = greater intensity of attribute; negative values (v) = reduction from baseline (b), positive v = increase from b. Sleep Quantity score r: 0-24 hours. Higher s = greater quantity of sleep. Change = (MOS score at observation period minus MOS score at b) divided by MOS score b.

    Time frame: Week 21, LOCF

  10. Change From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS): Optimal Sleep Subscale

    Optimal Sleep subscale of the MOS subject rated questionnaire to assess sleep quality and quantity. Optimal Sleep (1 of 7 subscales) was derived from sleep quantity: average hours of sleep each night during the past week. Number of subjects with response: YES=1 (optimal sleep: quantity of sleep was 7 or 8 hours per night) or No= 0 (no optimal sleep). Negative value indicates a decrease in attribute; positive value indicates an increase in attribute. Change = (MOS score at observation period minus MOS score at baseline \[b\]) divided by MOS score b.

    Time frame: Week 21, LOCF

  11. Change From Baseline in Hospital Anxiety and Depression Scale (HADS)

    Participant rated questionnaire with 2 subscales: HADS-A assesses generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D: state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale has 7 items; range: 0 (no anxiety or depression) to 3 (severe anxiety or depression). Total score 0 to 21 for each subscale; higher score = greater severity of symptoms. Negative value = reduction from baseline (b), positive value = increase from b. Change = (HADS score at observation period minus HADS score at b) divided by HADS score b.

    Time frame: Week 21, LOCF

07

Results

Posted Sep 9, 2010

Participant flow

Participant flow — Overall Study
MilestonePregabalin
Started136
Full analysis set135
Completed118
Not completed18
Withdrew: Lost to follow-up2
Withdrew: Adverse event6
Withdrew: Other7
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryPercent Change From Baseline in 28 Day Partial Seizure Rate During Treatment Observation Phase

28-day seizure rate (at observation period \[obs\]) = \[(number of seizures obs ) divided by (duration of period based on observed last dosing date and Visit 3 \[Week 9\] date)\] \* 28. Percent change = \[(28-day seizure rate obs minus 28-day seizure rate at baseline \[b\]) divided by 28-day seizure rate b\] \* 100. Negative values indicate a decrease in seizure frequency and positive values reflect an increase in seizure frequency.

Time frame:
Week 9 to Week 21 or End of Treatment (early termination)
Reported as:
Mean · percent change
Percent Change From Baseline in 28 Day Partial Seizure Rate During Treatment Observation Phase
percent changePregabalin
Percent Change From Baseline in 28 Day Partial Seizure Rate During Treatment Observation Phase-51.2 ± 45.2
Statistical analysis
  • Pregabalin · t-test, 2 sided · p = <.0001
SecondaryResponse Ratio (RR)

Response ratio (RR) = comparison between baseline 28-seizure frequency with the 12 week observation phase. RR = \[(28-day seizure rate in observation period \[obs\] minus 28-day seizure rate at baseline \[b\] ) divided by (28-day seizure rate obs plus 28-day seizure rate b)\] \* 100. Range: -100 to 100; negative values for the RR indicate reductions in seizures.

Time frame:
Week 9 to Week 21 or End of Treatment (early termination)
Reported as:
Mean · ratio
Response Ratio (RR)
ratioPregabalin
Response Ratio (RR)-45.1 ± 37.9
Statistical analysis
  • Pregabalin · t-test, 2 sided · p = <.0001
SecondaryPercent Change From Baseline in 28-Day Partial Seizure Frequency at Week 21

Percent change from Baseline = \[(28-day seizure rate at 21 weeks minus 28-day seizure rate at baseline \[b\]) divided by (28-day seizure rate b) \* 100. Negative values indicate a decrease in seizure frequency, positive values reflect an increase in seizure frequency.

Time frame:
Week 21 or End of Treatment (early termination)
Reported as:
Mean · percent change
Percent Change From Baseline in 28-Day Partial Seizure Frequency at Week 21
percent changePregabalin
Percent Change From Baseline in 28-Day Partial Seizure Frequency at Week 21-36.0 ± 55.8
Statistical analysis
  • Pregabalin · t-test, 2 sided · p = <.0001
SecondaryPercent Change From Baseline in Seizure Frequency in Participants Who Had <=6 Seizures and >6 Seizures During the Baseline Period

Negative values indicate a decrease in seizure frequency; positive values reflect an increase in seizure frequency.

Time frame:
Week 9 to Week 21 or End of Treatment (early termination)
Reported as:
Mean · percent change
Percent Change From Baseline in Seizure Frequency in Participants Who Had <=6 Seizures and >6 Seizures During the Baseline Period
percent changePregabalin
<= 6 seizures at Baseline (n=50)-57.9 ± 44.9
> 6 seizures at Baseline (n=71)-46.5 ± 45.1
Statistical analysis
  • Pregabalin · t-test, 2 sided · p = <.0001
  • Pregabalin · t-test, 2 sided · p = <.0001
SecondaryPercent of Seizure- Free Participants During the Treatment Observation Period

Seizure-free = no seizures during observation period (100 percent reduction in seizures from baseline).

Time frame:
Week 9 to Week 21 or Early Termination (end of treatment)
Reported as:
Number · percent of participants
Percent of Seizure- Free Participants During the Treatment Observation Period
percent of participantsPregabalin
Percent of Seizure- Free Participants During the Treatment Observation Period20.7
SecondaryPercent of Seizure Free Participants During the Last 4 Weeks of the Treatment Observation Period

Seizure-free = no seizures during last 4 weeks of observation period (100 percent reduction in seizures from baseline).

Time frame:
Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)
Reported as:
Number · percent of participants
Percent of Seizure Free Participants During the Last 4 Weeks of the Treatment Observation Period
percent of participantsPregabalin
Percent of Seizure Free Participants During the Last 4 Weeks of the Treatment Observation Period40.5
SecondaryPercent of Participants With >=50% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period
Time frame:
Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)
Reported as:
Number · percent of participants
Percent of Participants With >=50% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period
percent of participantsPregabalin
Percent of Participants With >=50% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period63.6
SecondaryPercent of Participants With >=75% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period
Time frame:
Week 17 through Week 21 (or Last 4 Weeks of Treatment after Week 9)
Reported as:
Number · percent of participants
Percent of Participants With >=75% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period
percent of participantsPregabalin
Percent of Participants With >=75% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period48.8
SecondaryTreatment Satisfaction: Patient General Impression to Change (PGIC)

Patient General Impression to Change (PGIC): participant rated instrument to measure participant's change in overall status since beginning study medication on a 7-point scale; range: 1 (very much improved) to 7 (very much worse). Not done = participant did not complete the PGIC.

Time frame:
Week 21, LOCF
Reported as:
Number · percent of participants
Treatment Satisfaction: Patient General Impression to Change (PGIC)
percent of participantsPregabalin
Week 21: Very Much Improved22.4
Week 21: Much Improved52.6
Week 21: Minimally Improved13.8
Week 21: No Change4.3
Week 21: Minimally Worse1.7
Week 21: Much Worse1.7
Week 21: Very Much Worse0.9
Week 21: Not Done2.6
LOCF: Very Much Improved20.7
LOCF: Much Improved51.1
LOCF: Minimally Improved12.6
LOCF: No Change4.4
LOCF: Minimally Worse1.5
LOCF: Much Worse1.5
LOCF: Very Much Worse0.7
LOCF: Not Done7.4
SecondaryChange From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS)

Participant rated questionnaire to assess sleep quality and quantity; 9-item overall sleep problems index and 7 subscales. Sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy subscale scores (s) rated 1 (all the time) to 6 (none of the time); transformed s; total range (r): 0 to 100; higher s = greater intensity of attribute; negative values (v) = reduction from baseline (b), positive v = increase from b. Sleep Quantity score r: 0-24 hours. Higher s = greater quantity of sleep. Change = (MOS score at observation period minus MOS score at b) divided by MOS score b.

Time frame:
Week 21, LOCF
Reported as:
Mean · scores on scale
Change From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS)
scores on scalePregabalin
Week 21: Sleep Disturbance-3.8 ± 20.9
LOCF: Sleep Disturbance-4.0 ± 21.1
Week 21: Snoring1.4 ± 35.4
LOCF: Snoring2.2 ± 34.3
Week 21: Awaken Short of Breath0.7 ± 32.4
LOCF: Awaken Short of Breath0.3 ± 30.9
Week 21: Adequacy4.2 ± 28.0
LOCF: Adequacy4.0 ± 26.9
Week 21: Somnolence0.4 ± 28.3
LOCF: Somnolence-0.8 ± 28.2
Week 21: 9-Item Overall Sleep Problem Index-2.2 ± 16.6
LOCF: 9-Item Overall Sleep Problem Index-2.5 ± 16.1
Week 21: Sleep Quantity0.4 ± 2.1
LOCF: Sleep Quantity0.4 ± 2.1
Statistical analysis
  • Pregabalin · t-test, 2 sided · p = 0.0552
  • Pregabalin · t-test, 2 sided · p = 0.0350
  • Pregabalin · t-test, 2 sided · p = 0.6743
  • Pregabalin · t-test, 2 sided · p = 0.4736
  • Pregabalin · t-test, 2 sided · p = 0.8173
  • Pregabalin · t-test, 2 sided · p = 0.9092
  • Pregabalin · t-test, 2 sided · p = 0.1091
  • Pregabalin · t-test, 2 sided · p = 0.0944
  • Pregabalin · t-test, 2 sided · p = 0.8928
  • Pregabalin · t-test, 2 sided · p = 0.7669
  • Pregabalin · t-test, 2 sided · p = 0.1698
  • Pregabalin · t-test, 2 sided · p = 0.0898
  • Pregabalin · t-test, 2 sided · p = 0.0465
  • Pregabalin · t-test, 2 sided · p = 0.0316
SecondaryChange From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS): Optimal Sleep Subscale

Optimal Sleep subscale of the MOS subject rated questionnaire to assess sleep quality and quantity. Optimal Sleep (1 of 7 subscales) was derived from sleep quantity: average hours of sleep each night during the past week. Number of subjects with response: YES=1 (optimal sleep: quantity of sleep was 7 or 8 hours per night) or No= 0 (no optimal sleep). Negative value indicates a decrease in attribute; positive value indicates an increase in attribute. Change = (MOS score at observation period minus MOS score at baseline \[b\]) divided by MOS score b.

Time frame:
Week 21, LOCF
Reported as:
Mean · scores on scale
Change From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS): Optimal Sleep Subscale
scores on scalePregabalin
Week 210.1 ± 0.6
LOCF0.1 ± 0.6
Statistical analysis
  • Pregabalin · t-test, 2 sided · p = 0.2187
  • Pregabalin · t-test, 2 sided · p = 0.1905
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS)

Participant rated questionnaire with 2 subscales: HADS-A assesses generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D: state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale has 7 items; range: 0 (no anxiety or depression) to 3 (severe anxiety or depression). Total score 0 to 21 for each subscale; higher score = greater severity of symptoms. Negative value = reduction from baseline (b), positive value = increase from b. Change = (HADS score at observation period minus HADS score at b) divided by HADS score b.

Time frame:
Week 21, LOCF
Reported as:
Mean · scores on scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS)
scores on scalePregabalin
Week 21: Anxiety-1.4 ± 3.7
LOCF: Anxiety-1.4 ± 3.8
Week 21: Depression-0.8 ± 4.8
LOCF: Depression-0.7 ± 4.7
Statistical analysis
  • Pregabalin · t-test, 2 sided · p = <.0001
  • Pregabalin · t-test, 2 sided · p = <.0001
  • Pregabalin · t-test, 2 sided · p = 0.0799
  • Pregabalin · t-test, 2 sided · p = 0.0846

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—8/136 (5.9%)91/136 (66.9%)
Most frequent serious events
Most frequent serious events
EventPregabalin
VertigoEar and labyrinth disorders2/136
Grand mal convulsionNervous system disorders2/136
Drug intoleranceGeneral disorders1/136
HypoglycemiaMetabolism and nutrition disorders1/136
HeadacheNervous system disorders1/136
Partial seizuresNervous system disorders1/136
Partial seizures with secondary generalizationNervous system disorders1/136
SyncopeNervous system disorders1/136
Psychotic disorderPsychiatric disorders1/136
Most frequent other events
Showing 10 of 66
Most frequent other events
EventPregabalin
SomnolenceNervous system disorders59/136
DizzinessNervous system disorders25/136
Weight increasedInvestigations19/136
HeadacheNervous system disorders12/136
VertigoEar and labyrinth disorders7/136
NauseaGastrointestinal disorders4/136
NasopharyngitisInfections and infestations4/136
CoughRespiratory, thoracic and mediastinal disorders3/136
PyrexiaGeneral disorders2/136
ArthralgiaMusculoskeletal and connective tissue disorders2/136

Baseline characteristics

Age, Customized
Age, Customized(participants)Pregabalin
18 - 44 years107
45 - 64 years25
>= 65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin
Female76
Male60
28-Day Seizure Rate
28-Day Seizure Rate(seizure rate)Pregabalin
Mean7.8 ± 14.0
28 day seizure frequency in Subjects with <= 6 and > 6 seizures during Baseline Period
28 day seizure frequency in Subjects with <= 6 and > 6 seizures during Baseline Period(seizures)Pregabalin
<=6 seizures2 ± 0.8
> 6 seizures12 ± 17.2
Medical Outcomes Study Sleep Scale
Medical Outcomes Study Sleep Scale(scores on scale)Pregabalin
Sleep Disturbance32.9 ± 20.9
Snoring40.1 ± 33.4
Awaken Short of Breath26.0 ± 24.8
Quantity of Sleep7.9 ± 1.9
Optimal Sleep0.5 ± 0.5
Sleep Adequacy64.6 ± 26.1
Somnolence39.2 ± 24.5
9-Item Sleep Problems Index33.4 ± 15.8
Hospital Anxiety and Depression Scale (HADS)
Hospital Anxiety and Depression Scale (HADS)(score on scale)Pregabalin
Anxiety Total Score8.8 ± 4.2
Depression Total Score7.3 ± 4.1
08

Study locations

8 sites
  • Pfizer Investigational Site
    Mexico, D. F. CP 06700, Mexico
  • Pfizer Investigational Site
    Acapulco, Guerrero 39670, Mexico
  • Pfizer Investigational Site
    Morelia, Michoacan CP 58000, Mexico
  • Pfizer Investigational Site
    Monterrey,, Nuevo Leon 64460, Mexico
  • Pfizer Investigational Site
    Monterrey, Nuevo Leon 64060, Mexico
  • Pfizer Investigational Site
    Aguascalientes, 20127, Mexico
  • Pfizer Investigational Site
    Chihuahua, 31238, Mexico
  • Pfizer Investigational Site
    Estado de México, CP 52763, Mexico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2006
First posted
Dec 5, 2006
Start
Mar 2007
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Sep 9, 2010
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00407797
Responsible party
Sponsor
First posted
Dec 5, 2006
Start date
Mar 2007
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Sep 9, 2010
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion